General
Preferred name
NEVIRAPINE
Synonyms
LAMIVUDINE ()
NSC 641530 ()
BI-RG 587 ()
NVP ()
Nevirapine (Viramune) ()
Viramune ()
NSC 641530,NVP ()
Nevirapine (NSC 641530) ()
BIRG-0587 ()
NSC-641530 ()
Nevirapine teva ()
Viramune Xr ()
BIRG 0587 ()
Nevirapine anhydrous ()
Nevirapina ()
Nevirapinum anhydrous ()
Nevirapine, anhydrous ()
BIRG0587 ()
Nevirapine-d4 ()
P&D ID
PD000851
CAS
129618-40-2
1051418-95-1
Tags
available
drug
Approved by
EMA
FDA
First approval
1996
Drug indication
HIV infection
Human immunodeficiency virus infection
Drug Status
approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) class antiretriviral drug.
(GtoPdb)
DESCRIPTION
Nevirapine is a non-nucleoside inhibitor of HIV-1 reverse transcriptase used to treat and prevent HIV/AIDS; with a Ki of 270 ¦ÌM[1].
PRICE
32
DESCRIPTION
Nevirapine is a non-nucleoside reverse transcriptase inhibitor used as part of a management regimen for HIV-1 virus infection.
(Enamine Bioactive Compounds)
DESCRIPTION
Nevirapine (NVP) is a benzodiazepine non-nucleoside reverse transcriptase inhibitor. In combination with other antiretroviral drugs, nevirapine reduces HIV viral loads and increases CD4 counts, thereby retarding or preventing the damage to the immune system and reducing the risk of developing AIDS.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
7
Organisms
4
Compound Sets
29
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
ChEMBL Approved Drugs
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
JUMP-Target 1 Compound Set
Ki Database
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
53
Molecular Weight
266.12
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
1
Ring Count
4
Aromatic Ring Count
2
cLogP
2.65
TPSA
58.12
Fraction CSP3
0.27
Chiral centers
0.0
Largest ring
7.0
QED
0.86
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
HIV
HIV-1 reverse transcriptase
Reverse Transcriptase
CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP3A4, CYP3A5
NNRT inhibitor
CYP2A6
Parasite
Indication
human immunodeficiency virus (HIV-1)
MOA
non-nucleoside reverse transcriptase inhibitor
Therapeutic Class
Anti-HIV Agents
Pathway
Anti-infection
Microbiology/virology
Proteases/Proteasome
Source data
